Master Rollover Protocol for Continued Safety Assessment of Study Drug
Sponsor: Eli Lilly and Company
Expanded Access
Sponsor score: 60
ClinicalTrials ID:NCT02632994
This study allows patients who benefited from a previous Lilly study to continue receiving the study drug. Eligible patients must have participated in a concluded study with an open addendum. They cannot be in other incompatible research. Interventions include oral administration of LY2503029 and LY3023414.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.
Eligibility Criteria
Inclusion Criteria
- To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.
Exclusion Criteria
- Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| UCLA Medical Center | 90505 | Torrance | California |
| Fort Wayne Oncology & Hematology | 46804 | Fort Wayne | Indiana |
| Sarah Cannon Cancer Center | 37203 | Nashville | Tennessee |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.